HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Prevacid Strong Switch Candidate, Experts Say; TAP Works on Follow-on

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Prevacid's bioavailability combined with the strong safety profile of the PPI class make it a good candidate for an Rx-to-OTC switch, experts say

You may also be interested in...



TAP Licenses Prevacid To Novartis For 2009 Switch

Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20

Prilosec OTC Making Inroads Into Abbott’s Prevacid

Abbott Labs plans to counter the launch of Prilosec OTC with a broad direct-to-consumer advertising campaign for its Rx proton pump inhibitor Prevacid

People In Brief

Perrigo promotes in pricing, planning

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

MacuHealth Asserts ‘Rigorous Process’ In Research Supporting Claims, But No Bill Of Health From NAD

Nestlé Partner Valbiotis Hails Trial Results For Prediabetes Supplement

FDA’s Linda Katz Takes MoCRA Questions At IBA Regulatory Workshop

Health And Wellness Weekly Trademarks Review: 19 September

See All
UsernamePublicRestriction

Register

RS126604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By